세계의 대장균 검사 시장 보고서 : 제품, 검사 유형, 최종 사용자, 지역별(2024-2032년)

The global E. coli testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032.

Escherichia coli (E. Coli) testing refers to the process of detecting and monitoring the presence of foodborne pathogens. E. Coli bacteria is usually found in contaminated food and water, cheese manufactured from raw milk, undercooked products, unpasteurized milk and raw fruits and vegetables. It can cause various diseases, such as food poisoning, pneumonia and urinary tract infections (UTIs). Some of the clinical testing methods for the detection of E. Coli include enzyme immunoassays (EIA) and polymerase chain reaction (PCR) tests, along with environmental testing methods, such as enzyme-substrate, membrane filtration and multiple tube fermentation (MTF). These techniques aid in obtaining an accurate and quantitative measure of total coliform and bacteria present in the sample.

The increasing prevalence of water-borne diseases, such as diarrhea and hemolytic uremic syndrome (HUS), along with the growing need for clean potable water across the globe, is one of the key factors creating a positive outlook for the market. E. Coli tests can aid in monitoring the quality of surface and drinking water to prevent the spread of illnesses and diseases. Furthermore, the widespread adoption of the enzyme-substrate test as a presence or absence (P/A) test is also driving the market growth. These tests are easy to perform, do not require sophisticated laboratory equipment and use hydrolyzable fluorogenic substrates to detect the presence of various enzymes produced by the bacteria. Additionally, various technological advancements, such as the development of innovative bacterial diagnostic instruments and water testing methods, are contributing to the market growth. Other factors, including increasing health consciousness among the masses, along with extensive research and development (R&D) activities in the field of microbiology, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global E. coli testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, test type and end user.

Breakup by Product:

Consumables

Instruments

Breakup by Test Type:

Environmental Test

Membrane Filtration (MF)

Multiple Tube Fermentation (MTF)

Enzyme Substrate Methods

Clinical Test

Polymerase Chain Reaction (PCR) Tests

Enzyme Immunoassays (EIA)

Others

Breakup by End User:

Hospitals and Clinics

Diagnostic Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accugen Laboratories Inc., Alere Inc. (Abbott Laboratories), BD (Becton Dickinson and Company), bioMerieux (INSTITUT MERIEUX), Bio-RAD Laboratories Inc., Enzo Life Sciences Inc. (Enzo Biochem Inc.), Idexx Laboratories Inc., Johnson & Johnson, Meridian Bioscience Inc., Nanologix Inc., Pro-Lab Diagnostics, Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global E. coli testing market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global E. coli testing market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the test type?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global E. coli testing market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global E. Coli Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Test Type

• 7.1 Environmental Test
  • 7.1.1 Market Trends
  • 7.1.2 Major Types
    • 7.1.2.1 Membrane Filtration (MF)
    • 7.1.2.2 Multiple Tube Fermentation (MTF)
    • 7.1.2.3 Enzyme Substrate Methods
  • 7.1.3 Market Forecast
• 7.2 Clinical Test
  • 7.2.1 Market Trends
  • 7.2.2 Major Types
    • 7.2.2.1 Polymerase Chain Reaction (PCR) Tests
    • 7.2.2.2 Enzyme Immunoassays (EIA)
    • 7.2.2.3 Others
  • 7.2.3 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostic Laboratories
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Accugen Laboratories Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Alere Inc. (Abbott Laboratories)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 BD (Becton Dickinson and Company)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 bioMerieux (INSTITUT MERIEUX)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Bio-RAD Laboratories Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Enzo Life Sciences Inc. (Enzo Biochem Inc.)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Idexx Laboratories Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Johnson & Johnson
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Meridian Bioscience Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Nanologix Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Pro-Lab Diagnostics
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Qiagen N.V.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis
  • 14.3.13 Thermo Fisher Scientific Inc.
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis